The prevalence of anemia in patients with chronic kidney disease

McClellan, William M.; Aronoff, Stephen L.; Bolton, W. Kline; Hood, Sally A.; Lorber, Daniel; Tang, Kezhen L.; Tse, Thomas F.; Wasserman, Brian; Leiserowitz, Marc

doi:10.1185/030079904x2763

Cited by 422 publications

(330 citation statements)

References 19 publications

Supporting

Mentioning

282

Contrasting

Unclassified

Order By: Relevance

“…We observed a tendency toward gradual increased serum hemoglobin levels in all treated patients. This could be of clinical relevance given that the prevalence of anemia increases with deteriorating renal function 28 and is related to cardiac complications 29 and cerebrovascular events. 30 In this context, it is noteworthy that data from both experimental and human studies have suggested a role of renal sympathetic nerves in the modulation of erythropoiesis.…”

Section: Discussionmentioning

confidence: 99%

Renal Denervation in Moderate to Severe CKD

Hering

Mahfoud

Walton

et al. 2012

Journal of the American Society of Nephrology

324

224

View full text Add to dashboard Cite

Sympathetic activation contributes to the progression of CKD and is associated with adverse cardiovascular outcomes. Ablation of renal sympathetic nerves reduces sympathetic nerve activity and BP in patients with resistant hypertension and preserved renal function, but whether this approach is safe and effective in patients with an estimated GFR (eGFR) , 45 ml/min per 1.73 m 2 is unknown. We performed bilateral renal denervation in 15 patients with resistant hypertension and stage 3-4 CKD (mean eGFR, 31 ml/min per 1.73 m 2 ). We used CO 2 angiography in six patients to minimize exposure to contrast agents.Estimated GFR remained unchanged after the procedure, irrespective of the use of CO 2 angiography. Mean baseline BP 6 SD was 174622/91616 mmHg despite the use of 5.661.3 antihypertensive drugs. Mean changes in office systolic and diastolic BP at 1, 3, 6, and 12 months were 234/214, 225/211, 232/215, and 233/219 mmHg, respectively. Night-time ambulatory BP significantly decreased (P,0.05), restoring a more physiologic dipping pattern. In conclusion, this study suggests a favorable short-term safety profile and beneficial BP effects of catheter-based renal nerve ablation in patients with stage 3-4 CKD and resistant hypertension.

show abstract

Section: Discussionmentioning

confidence: 99%

Renal Denervation in Moderate to Severe CKD

Hering

Mahfoud

Walton

et al. 2012

Journal of the American Society of Nephrology

324

224

View full text Add to dashboard Cite

show abstract

“…Anaemia is a common finding in chronic kidney disease (CKD), affecting over half of all patients [1]. Diabetes, as the most common single cause of CKD in the Western world, is therefore also the most common cause of renal anaemia.…”

Section: Introductionmentioning

confidence: 99%

Anaemia in diabetes: is there a rationale to TREAT?

et al. 2006

View full text Add to dashboard Cite

“…A nemia is commonly associated with chronic kidney disease (CKD) (1)(2)(3) and contributes to the morbidity and mortality and reduced quality of life in these patients (4 -10). Erythropoiesis-stimulating agents (ESA) and clinical practice guidelines have been beneficial in managing renal anemia (11)(12)(13)(14)(15), and anemia correction has been associated with improved patient outcomes (16,17).…”

mentioning

confidence: 99%

Once-Monthly Subcutaneous C.E.R.A. Maintains Stable Hemoglobin Control in Patients with Chronic Kidney Disease on Dialysis and Converted Directly from Epoetin One to Three Times Weekly

Sułowicz

Locatelli

Ryckelynck

et al. 2007

Clinical Journal of the American Society of Nephrology

133

114

View full text Add to dashboard Cite

Background: C.E.R.A., a continuous erythropoietin receptor activator, is in development to provide anemia correction and stable maintenance of hemoglobin (Hb) levels at extended administration intervals in patients with chronic kidney disease (CKD). This study examined its efficacy and safety when administered up to once monthly in patients who have CKD and are on dialysis and randomly convert directly from epoetin ␣ or ␤ one to three times weekly.Design, setting, participants, and measurements: In this three-arm, comparator-controlled, open-label, randomized, parallelgroup, Phase III study, 572 dialysis patients (>18 yr) who were receiving stable subcutaneous epoetin one to three times weekly were randomly assigned (1:1:1) to continue epoetin or to receive subcutaneous C.E.R.A. once monthly or twice monthly for 52 wk. Conclusions: Subcutaneous C.E.R.A. once or twice monthly successfully maintained tight and stable Hb levels in patients who were on dialysis and randomly converted directly from epoetin one to three times weekly.

show abstract

The prevalence of anemia in patients with chronic kidney disease

Abstract: Anemia was present in 47.7% of 5222 predialysis patients with chronic kidney disease. Prevalence of anemia increased as kidney function decreased. Certain subgroups are at increased risk for anemia.

Cited by 422 publications

References 19 publications

Renal Denervation in Moderate to Severe CKD

Renal Denervation in Moderate to Severe CKD

Anaemia in diabetes: is there a rationale to TREAT?

Once-Monthly Subcutaneous C.E.R.A. Maintains Stable Hemoglobin Control in Patients with Chronic Kidney Disease on Dialysis and Converted Directly from Epoetin One to Three Times Weekly

Contact Info

Product

Resources

About